Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 2897 Download: 258 Citations: 4

Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Jihyun An, Ju Hyun Shim

Clin Mol Hepatol. 2022;28(2):267-268. Published online January 18, 2022

DOI: https://doi.org/10.3350/cmh.2022.0013

View: 1879 Download: 39

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

DOI: https://doi.org/10.3350/cmh.2021.0412

View: 5354 Download: 35 Citation: 1

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

View: 3193 Download: 182 Citations: 2

The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages

Linda Beenet

Clin Mol Hepatol. 2021;27(3):510-511. Published online March 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0058

View: 2675 Download: 133 Citation: 1

Clinical and serological prognostic markers in primary biliary cholangitis

Markus Wilhelmi

Clin Mol Hepatol. 2021;27(2):360-361. Published online March 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0088

View: 2502 Download: 96

A dilemma that probably would never resolve

Ravi Thanage, Shubham Jain, Sanjay Chandnani, Pravin Rathi

Clin Mol Hepatol. 2021;27(1):219-220. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0274

View: 2394 Download: 68

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

View: 2625 Download: 63 Citations: 2

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park, Soo Han Bae

Clin Mol Hepatol. 2020;26(4):577-578. Published online September 17, 2020

DOI: https://doi.org/10.3350/cmh.2020.0143

View: 2694 Download: 61 Citation: 1

Macro-aspartate aminotransferase in a healthy woman

Maria Lorubbio, Agostino Ognibene, Benedetta Salvadori, Alessandra Fanelli, Giacomo Laffi

Clin Mol Hepatol. 2020;26(3):378-381. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0069

View: 3640 Download: 116 Citations: 2

How does low-level viremia affect the prognosis of patients with chronic hepatitis B?

Hye Won Lee, Beom Kyung Kim

Clin Mol Hepatol. 2020;26(3):376-377. Published online June 11, 2020

DOI: https://doi.org/10.3350/cmh.2020.0121

View: 3386 Download: 108 Citation: 1

Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Jung Hwan Yu

Clin Mol Hepatol. 2020;26(2):240-241. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0048

View: 3076 Download: 40

Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma

Hwi Young Kim, Jean-François Dufour

Clin Mol Hepatol. 2020;26(2):238-239. Published online March 18, 2020

DOI: https://doi.org/10.3350/cmh.2020.0051

View: 3197 Download: 56 Citation: 1

Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?

Hyuk Soo Eun

Clin Mol Hepatol. 2020;26(2):236-237. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0040

View: 2696 Download: 44

A challenge in distinguishing between acute hepatitis B and acute exacerbation of chronic hepatitis B

Yang-Hyun Baek

Clin Mol Hepatol. 2020;26(2):233-235. Published online April 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0039

View: 3356 Download: 109

Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps

Rodrigo Cañada Trofo Surjan, Elizabeth Santana dos Santos, Sergio do Prado Silveira, Fabio Ferrari Makdissi, Marcel Autran Cesar Machado

Clin Mol Hepatol. 2020;26(2):231-232. Published online November 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.0084

View: 3369 Download: 83 Citations: 2

Viewed By 4174	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 3580	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 2858	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2805	Recent updates on the management of autoimmune hepatitis
Viewed By 2726	Identification of high-risk subjects in nonalcoholic fatty liver disease

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Letter to the Editor